Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 11/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809537 | 0.79 | MC4R (0.53) | MC4RDPP7 | |
| SCHEMBL4678276 | 0.75 | MC4R (0.41) | MC4R | |
| SCHEMBL6604084 | 0.74 | MC4R (0.46) | MC4R | |
| SCHEMBL5337815 | 0.71 | L3MBTL1 (0.45) | MC4RLMNAKMT2ASMN1; SMN2GLA | |
| SCHEMBL5483957 | 0.69 | MC4R (0.47) | MC4RLMNASMN1; SMN2GLATSHR | |
| SCHEMBL6156123 | 0.68 | KDM4E (0.48) | LMNAUSP2KMT2ASMN1; SMN2GLA | |
| SCHEMBL5475954 | 0.67 | MC4R (0.49) | MC4RLMNAGLATSHR | |
| SCHEMBL6607073 | 0.67 | MC4R (0.45) | MC4RLMNASMN1; SMN2GLATSHR | |
| SCHEMBL5339603 | 0.67 | MC4R (0.45) | MC4RLMNASMN1; SMN2GLATSHR | |
| SCHEMBL5403213 | 0.67 | MC4R (0.41) | MC4RHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053933-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053933-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | MC3R, MC1R, MC5R | MC4R 4/4885DPP7 2162/4885LMNA 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.